The androgen receptor malignancy shift in prostate cancer

被引:22
作者
Copeland, Ben T. [1 ]
Pal, Sumanta K. [1 ]
Bolton, Eric C. [2 ]
Jones, Jeremy O. [1 ]
机构
[1] City Hope Natl Med Ctr, Dept Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL USA
关键词
androgen receptor; ChIP-seq; prostate cancer; tumorigenesis; FORKHEAD BOX A1; GENE FUSIONS; ETS FAMILY; TRANSCRIPTION FACTORS; MICE LACKING; ERG REARRANGEMENT; VENTRAL PROSTATE; REDUCE TRIAL; CELL-DEATH; CASTRATION;
D O I
10.1002/pros.23497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAndrogens and the androgen receptor (AR) are necessary for the development, function, and homeostatic growth regulation of the prostate gland. However, once prostate cells are transformed, the AR is necessary for the proliferation and survival of the malignant cells. This change in AR function appears to occur in nearly every prostate cancer. We have termed this the AR malignancy shift. MethodsIn this review, we summarize the current knowledge of the AR malignancy shift, including the DNA-binding patterns that define the shift, the transcriptome changes associated with the shift, the putative drivers of the shift, and its clinical implications. ResultsIn benign prostate epithelial cells, the AR primarily binds consensus AR binding sites. In carcinoma cells, the AR cistrome is dramatically altered, as the AR associates with FOXA1 and HOXB13 motifs, among others. This shift leads to the transcription of genes associated with a malignant phenotype. In model systems, some mutations commonly found in localized prostate cancer can alter the AR cistrome, consistent with the AR malignancy shift. Current evidence suggests that the AR malignancy shift is necessary but not sufficient for transformation of prostate epithelial cells. ConclusionsReinterpretation of prostate cancer genomic classification systems in light of the AR malignancy shift may improve our ability to predict clinical outcomes and treat patients appropriately. Identifying and targeting the molecular factors that contribute to the AR malignancy shift is not trivial but by doing so, we may be able to develop new strategies for the treatment or prevention of prostate cancer.
引用
收藏
页码:521 / 531
页数:11
相关论文
共 102 条
[1]   The Molecular Taxonomy of Primary Prostate Cancer [J].
Abeshouse, Adam ;
Ahn, Jaeil ;
Akbani, Rehan ;
Ally, Adrian ;
Amin, Samirkumar ;
Andry, Christopher D. ;
Annala, Matti ;
Aprikian, Armen ;
Armenia, Joshua ;
Arora, Arshi ;
Auman, J. Todd ;
Balasundaram, Miruna ;
Balu, Saianand ;
Barbieri, Christopher E. ;
Bauer, Thomas ;
Benz, Christopher C. ;
Bergeron, Alain ;
Beroukhim, Rameen ;
Berrios, Mario ;
Bivol, Adrian ;
Bodenheimer, Tom ;
Boice, Lori ;
Bootwalla, Moiz S. ;
dos Reis, Rodolfo Borges ;
Boutros, Paul C. ;
Bowen, Jay ;
Bowlby, Reanne ;
Boyd, Jeffrey ;
Bradley, Robert K. ;
Breggia, Anne ;
Brimo, Fadi ;
Bristow, Christopher A. ;
Brooks, Denise ;
Broom, Bradley M. ;
Bryce, Alan H. ;
Bubley, Glenn ;
Burks, Eric ;
Butterfield, Yaron S. N. ;
Button, Michael ;
Canes, David ;
Carlotti, Carlos G. ;
Carlsen, Rebecca ;
Carmel, Michel ;
Carroll, Peter R. ;
Carter, Scott L. ;
Cartun, Richard ;
Carver, Brett S. ;
Chan, June M. ;
Chang, Matthew T. ;
Chen, Yu .
CELL, 2015, 163 (04) :1011-1025
[2]   Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer [J].
Agoulnik, Irina U. ;
Vaid, Ajula ;
Nakka, Manjula ;
Alvarado, Misty ;
Bingman, William E., III ;
Erdem, Halime ;
Frolov, Anna ;
Smith, Carolyn L. ;
Ayala, Gustavo E. ;
Ittmann, Michael M. ;
Weigel, Nancy L. .
CANCER RESEARCH, 2006, 66 (21) :10594-10602
[3]   Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].
Andriole, G ;
Bostwick, D ;
Brawley, O ;
Gomella, L ;
Tindall, D ;
Breed, S ;
Somerville, M ;
Rittmaster, R .
JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317
[4]   Punctuated Evolution of Prostate Cancer Genomes [J].
Baca, Sylvan C. ;
Prandi, Davide ;
Lawrence, Michael S. ;
Mosquera, Juan Miguel ;
Romanel, Alessandro ;
Drier, Yotam ;
Park, Kyung ;
Kitabayashi, Naoki ;
MacDonald, Theresa Y. ;
Ghandi, Mahmoud ;
Van Allen, Eliezer ;
Kryukov, Gregory V. ;
Sboner, Andrea ;
Theurillat, Jean-Philippe ;
Soong, T. David ;
Nickerson, Elizabeth ;
Auclair, Daniel ;
Tewari, Ashutosh ;
Beltran, Himisha ;
Onofrio, Robert C. ;
Boysen, Gunther ;
Guiducci, Candace ;
Barbieri, Christopher E. ;
Cibulskis, Kristian ;
Sivachenko, Andrey ;
Carter, Scott L. ;
Saksena, Gordon ;
Voet, Douglas ;
Ramos, Alex H. ;
Winckler, Wendy ;
Cipicchio, Michelle ;
Ardlie, Kristin ;
Kantoff, Philip W. ;
Berger, Michael F. ;
Gabriel, Stacey B. ;
Golub, Todd R. ;
Meyerson, Matthew ;
Lander, Eric S. ;
Elemento, Olivier ;
Getz, Gad ;
Demichelis, Francesca ;
Rubin, Mark A. ;
Garraway, Levi A. .
CELL, 2013, 153 (03) :666-677
[5]   ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients [J].
Baena, Esther ;
Shao, Zhen ;
Linn, Douglas E. ;
Glass, Kimberly ;
Hamblen, Melanie J. ;
Fujiwara, Yuko ;
Kim, Jonghwan ;
Minh Nguyen ;
Zhang, Xin ;
Godinho, Frank J. ;
Bronson, Roderick T. ;
Mucci, Lorelei A. ;
Loda, Massimo ;
Yuan, Guo-Cheng ;
Orkin, Stuart H. ;
Li, Zhe .
GENES & DEVELOPMENT, 2013, 27 (06) :683-698
[6]   Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer [J].
Beltran, Himisha ;
Prandi, Davide ;
Mosquera, Juan Miguel ;
Benelli, Matteo ;
Puca, Loredana ;
Cyrta, Joanna ;
Marotz, Clarisse ;
Giannopoulou, Eugenia ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana ;
Tomlins, Scott A. ;
Nanus, David M. ;
Tagawa, Scott T. ;
Van Allen, Eliezer M. ;
Elemento, Olivier ;
Sboner, Andrea ;
Garraway, Levi A. ;
Rubin, Mark A. ;
Demichelis, Francesca .
NATURE MEDICINE, 2016, 22 (03) :298-305
[7]   SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling [J].
Blattner, Mirjam ;
Liu, Deli ;
Robinson, Brian D. ;
Huang, Dennis ;
Poliakov, Anton ;
Gao, Dong ;
Nataraj, Srilakshmi ;
Deonarine, Lesa D. ;
Augello, Michael A. ;
Sailer, Verena ;
Ponnala, Lalit ;
Ittmann, Michael ;
Chinnaiyan, Arul M. ;
Sboner, Andrea ;
Chen, Yu ;
Rubin, Mark A. ;
Barbieri, Christopher E. .
CANCER CELL, 2017, 31 (03) :436-451
[8]   CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer [J].
Burkhardt, Lia ;
Fuchs, Sarah ;
Krohn, Antje ;
Masser, Sawinee ;
Mader, Malte ;
Kluth, Martina ;
Bachmann, Frederik ;
Huland, Hartwig ;
Steuber, Thomas ;
Graefen, Markus ;
Schlomm, Thorsten ;
Minner, Sarah ;
Sauter, Guido ;
Sirma, Hueseyin ;
Simon, Ronald .
CANCER RESEARCH, 2013, 73 (09) :2795-2805
[9]   Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer [J].
Butler, Miriam S. ;
Roshan-Moniri, Mani ;
Hsing, Michael ;
Lau, Desmond ;
Kim, Ari ;
Yen, Paul ;
Mroczek, Marta ;
Nouri, Mannan ;
Lien, Scott ;
Axerio-Cilies, Peter ;
Dalal, Kush ;
Yau, Clement ;
Ghaidi, Fariba ;
Guo, Yubin ;
Yamazaki, Takeshi ;
Lawn, Sam ;
Gleave, Martin E. ;
Gregory-Evans, Cheryl Y. ;
McIntosh, Lawrence P. ;
Cox, Michael E. ;
Rennie, Paul S. ;
Cherkasov, Artem .
ONCOTARGET, 2017, 8 (26) :42438-42454
[10]   c-jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer [J].
Cai, Changmeng ;
Hsieh, Chen-Lin ;
Shemshedini, Lirim .
MOLECULAR CANCER RESEARCH, 2007, 5 (07) :725-735